Navigating the Latest Evidence and Strategies for Renal Risk Reduction in T2D

Gain expert-informed strategies for addressing renal risk in patients with type 2 diabetes and chronic kidney disease by understanding the latest guidelines and evidence and the emerging role of GLP-1 RAs, through Medical Minutes with accompanying slides, ClinicalThought commentaries, and a text module.

Share

Program Content

Events

Activities

GLP-1 RAs for CKD in T2D
Expanding Our Therapeutic Horizons: The Role of GLP-1 Receptor Agonists in Managing CKD in Type 2 Diabetes
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2024

Expires: October 30, 2025

Faculty

cover img faculity

David Charytan, MD, MSc

Norman S. Wilker Professor of Medicine
Director, Nephrology Division
New York University Grossman School of Medicine
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the American Kidney Fund.

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

American Kidney Fund

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner